New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For NVO;VPHM;INFI;MRK;AGN;SHPG;SGEN;OREX;AMGN;SNY;JNJ;PFE From The Last 14 Days
Check below for free stories on NVO;VPHM;INFI;MRK;AGN;SHPG;SGEN;OREX;AMGN;SNY;JNJ;PFE the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
September 12, 2014
05:09 EDTAGNAllergan comments on Pershing Square delivery of additional requests
Allergan (AGN) commented on Pershing Square Capital Management delivery of additional requests from stockholders owning 1.5% of Allerganís shares to call a Special Meeting of Stockholders. Allergan will review these requests in addition to the requests from stockholders owning 2.8% of Allerganís shares that were delivered on September 3. The company issued the following statement: Notwithstanding Pershing Square and Valeant Pharmaceuticals (VRX) efforts to change the subject, Allergan recognizes that what actually matters is value, and thatís what the company is focusing on delivering to stockholders. In that regard, Allerganís current strategic plan is expected to deliver a compounded annual growth rate of greater than 20% EPS growth, including estimated 2016 EPS at approximately $10.00. Allergan has already scheduled the Special Meeting for December 18. As such, the delivery of additional requests for the Special Meeting by Pershing Square is not a meaningful development. The lawsuit in California is seeking an order barring Valeant, Pershing Square, Ackman, and entities affiliated with them from voting shares that Allergan believes were acquired in violation of the federal securities laws, including insider trading. If Allerganís motion for a preliminary injunction is granted, it would prevent Valeant, Pershing Square, and Ackman from voting their shares at any meeting of stockholders.
September 11, 2014
17:12 EDTNVONovo Nordisk Saxenda receives positive 14-1 vote in favor of approval from FDA
Subscribe for More Information
16:21 EDTOREXOn The Fly: Closing Wrap
Subscribe for More Information
12:42 EDTOREXOrexigen falls after FDA requires warnings on Contrave label
Subscribe for More Information
11:08 EDTAGNAllergan shareholders owning 35% to ask for meeting, Reuters says
Subscribe for More Information
11:07 EDTOREXOptions with decreasing implied volatility
Subscribe for More Information
10:59 EDTOREXArena competition picks up after Contrave approval, says Piper Jaffray
Subscribe for More Information
10:49 EDTOREXHigh option volume stocks
Subscribe for More Information
10:29 EDTOREXOrexigen falls, levels to watch
Trading is volatile on very heavy volume nearing three times the daily average. At the current price of $5.41, next support is at $5.30, the low of the day, and then at $4.60 which is the 52-week low. Resistance is at $5.90, the prior session closing price.
09:52 EDTAGNValeant to submit consent from 35% of Allergan holders, CNBC reports
Subscribe for More Information
08:01 EDTOREXOrexigen Contrave could have stronger launch than peers, says Wells Fargo
After the FDA approved Orexigen's (OREX) Contrave as a treatment option for chronic weight management, Wells Fargo does not believe the label included any significant surprises. The firm thinks multiple factors increase the chances that Contrave's launch will be stronger than two other weight loss drugs that were launched in recent years by VIVUS and Arena Pharmaceuticals (ARNA). The firm keeps an Outperform rating on Orexigen.
07:31 EDTNVOFDA Endocrinologic and Metabolic Drugs Advisory Committee to hold a meeting
Subscribe for More Information
07:11 EDTJNJMedivation price target raised to $112 from $89 at Stifel
Subscribe for More Information
07:06 EDTOREXOrexigen's Contrave weight management tablets approved by FDA
Orexigen Therapeutics and Takeda Pharmaceuticals U.S.A. jointly announced that the FDA has approved Contrave extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index indicating obese or overweight, in the presence of at least one weight-related comorbid condition. Takeda is planning to commercially launch Contrave in the fall.
06:49 EDTOREXFDA approves weight management drug Contrave
The U.S. Food and Drug Administration yesterday approved Contrave as treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity. The drug is approved for use in adults with a body mass index of 30 or greater or adults with a BMI of 27 or greater who have at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. Contrave is a combination of two FDA-approved drugs, naltrexone and bupropion, in an extended-release formulation. The effectiveness of Contrave was evaluated in multiple clinical trials that included approximately 4,500 obese and overweight patients with and without significant weight-related conditions treated for one year. Contrave is distributed by Takeda Pharmaceuticals America (TKPYY) for Orexigen Therapeutics (OREX).
05:27 EDTSNYGenzyme announces positive interim results from Lemtrada extension study
Subscribe for More Information
September 10, 2014
18:27 EDTOREXOrexigen trading halted, pending news
Subscribe for More Information
16:00 EDTMRKOptions Update; September 10, 2014
Subscribe for More Information
11:06 EDTNVOHigh option volume stocks
Subscribe for More Information
10:14 EDTJNJJohnson & Johnson says off to 'very good start' this year
Subscribe for More Information
<< 1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use